Literature DB >> 12408527

Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation.

K M Boberg1, A Bergquist, S Mitchell, A Pares, F Rosina, U Broomé, R Chapman, O Fausa, T Egeland, G Rocca, E Schrumpf.   

Abstract

BACKGROUND: Primary sclerosing cholangitis (PSC) confers a high risk of cholangiocarcinoma (CC) development. Since patients at risk of CC may be selected for early liver transplantation, it is a challenge to identify any predisposing factors. We compared the presentation and natural history of a large number of PSC patients with and without later CC development to identify features associated with risk of CC.
METHODS: Clinical and laboratory data from presentation and follow-up were collected from 394 PSC patients from five European countries. The cohort included 48 (12.2%) patients with CC.
RESULTS: CC was diagnosed within the first year after diagnosis of PSC in 24 (50%) cases and in 13 (27%) patients at intended liver transplantation. Jaundice, pruritus, abdominal pain and fatigue were significantly more frequent at diagnosis of PSC in the group that developed CC, but not after exclusion of cases diagnosed within the first year. Inflammatory bowel disease was diagnosed at least 1 year before PSC more often among patients with CC development than among those without (90% and 65%, respectively: P = 0.001). The duration of inflammatory bowel disease before diagnosis of PSC was significantly longer in patients who developed CC than in the remaining group (17.4 years and 9.0 years, respectively: P=0.009 in multivariate analysis).
CONCLUSIONS: A high proportion of CC cases is diagnosed within the first year after diagnosis of PSC. A long history of inflammatory bowel disease is a risk factor for CC development.

Entities:  

Mesh:

Year:  2002        PMID: 12408527     DOI: 10.1080/003655202760373434

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  65 in total

1.  Hepatic and extrahepatic malignancies and primary sclerosing cholangitis.

Authors:  E Schrumpf; K M Boberg
Journal:  Gut       Date:  2003-02       Impact factor: 23.059

Review 2.  Endoscopic management of benign biliary strictures.

Authors:  Kavel H Visrodia; James H Tabibian; Todd H Baron
Journal:  World J Gastrointest Endosc       Date:  2015-08-25

3.  Results of a phase I-II study on intraductal confocal microscopy (IDCM) in patients with common bile duct (CBD) stenosis.

Authors:  M Giovannini; E Bories; G Monges; C Pesenti; F Caillol; J R Delpero
Journal:  Surg Endosc       Date:  2011-03-18       Impact factor: 4.584

Review 4.  Extraintestinal manifestations in inflammatory bowel disease.

Authors:  Silvio Danese; Stefano Semeraro; Alfredo Papa; Italia Roberto; Franco Scaldaferri; Giuseppe Fedeli; Giovanni Gasbarrini; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

Review 5.  Management of primary sclerosing cholangitis: conventions and controversies.

Authors:  Natasha Chandok; Gideon M Hirschfield
Journal:  Can J Gastroenterol       Date:  2012-05       Impact factor: 3.522

Review 6.  Update in the Care and Management of Patients with Primary Sclerosing Cholangitis.

Authors:  Mai Sedki; Cynthia Levy
Journal:  Curr Gastroenterol Rep       Date:  2018-06-09

Review 7.  MicroRNAs and benign biliary tract diseases.

Authors:  Sergio A Gradilone; Steven P O'Hara; Tetyana V Masyuk; Maria Jose Lorenzo Pisarello; Nicholas F LaRusso
Journal:  Semin Liver Dis       Date:  2015-01-29       Impact factor: 6.115

Review 8.  Cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

9.  Immunohistochemical study of DPC4 and p53 proteins in gallbladder and bile duct cancers.

Authors:  Shih-Chang Chuang; King-Teh Lee; Kun-Bow Tsai; Pai-Ching Sheen; Eishi Nagai; Kazuhiro Mizumoto; Masao Tanaka
Journal:  World J Surg       Date:  2004-09-29       Impact factor: 3.352

10.  MicroRNAs in Cholangiopathies.

Authors:  Steven P O'Hara; Sergio A Gradilone; Tetyana V Masyuk; James H Tabibian; Nicholas F LaRusso
Journal:  Curr Pathobiol Rep       Date:  2014-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.